Exelixis Inc. — Sponsor Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

3 Recruiting

10 Completed trials

18 Countries active

14 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase I (Other)

Phase III: 6 Phase II/III: 2 Phase IV: 1 Phase I: 1 Phase I (Other): 3

100%

10 of 10 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Hormone receptor positive breast cancer 2 Renal cell carcinoma 2 Ovarian cancer 1 Thyroid cancer 1 Bladder cancer 1 Endometrial cancer metastatic 1 Head and neck cancer metastatic 1 Non-small cell lung cancer stage IV 1 Prostate cancer metastatic 1 Squamous cell carcinoma of head and neck 1 Endometrial cancer 1 Non-small cell lung cancer 1

Top IMPs

CABOZANTINIB 5 N-(4-FLUOROPHENYL)-N-(4-((7-METHOXY-6-(METHYLCARBAMOYL)QUINOLIN-4- YL)OXY)PHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE 5 ATEZOLIZUMAB 3 NIVOLUMAB 3 IPILIMUMAB 2 NIVOLUMAB, RELATLIMAB 1 PEMBROLIZUMAB 1 PREDNISONE 1 REGORAFENIB 1 SORAFENIB 1 SUNITINIB 1

All trials

13 total

A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Ca… Recruiting

2022-501703-27-00 Phase III 14 countries N-(4-FLUOROPHENYL)-N-(4-((7-METHOXY-6-(METHYLCARBAMOYL)QUINOLIN-4- YL)OXY)PHENYL…
A Phase 2/3 clinical trial with zanzalintinib versus everolimus Recruiting

2025-521043-20-00 Phase II/III 8 countries N-(4-FLUOROPHENYL)-N-(4-((7-METHOXY-6-(METHYLCARBAMOYL)QUINOLIN-4- YL)OXY)PHENYL…
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo… Recruiting

2023-506308-24-00 Phase II/III 13 countries N-(4-FLUOROPHENYL)-N-(4-((7-METHOXY-6-(METHYLCARBAMOYL)QUINOLIN-4- YL)OXY)PHENYL…
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety tolerability, pharmacokinetics… Ended

2023-510061-10-00 Phase I (Other) 7 countries IPILIMUMAB; N-(4-FLUOROPHENYL)-N-(4-((7-METHOXY-6-(METHYLCARBAMOYL)QUINOLIN-4- Y…
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) Ended

2024-512915-33-00 Phase III 7 countries ATEZOLIZUMAB; N-(4-FLUOROPHENYL)-N-(4-((7-METHOXY-6-(METHYLCARBAMOYL)QUINOLIN-4-…
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with I… Ended

2024-515617-18-00 Phase I 5 countries
Study of Cabozantinib in Combination With Atezolizumab compared to Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castratio… Ended

2024-516481-11-00 Phase III 9 countries ATEZOLIZUMAB; CABOZANTINIB; PREDNISONE
This is a randomized, double-blind, controlled trial to evaluate the efficacy and safety of cabozantinib in combination with nivolumab and i… Ended

2024-515616-47-00 Phase III 9 countries CABOZANTINIB; IPILIMUMAB; NIVOLUMAB
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated… Ended

2024-516478-31-00 Phase III 3 countries CABOZANTINIB
A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced H… Ended

2024-516479-34-00 Phase III 5 countries ATEZOLIZUMAB; CABOZANTINIB; SORAFENIB
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Adv… Ended

2024-516477-73-00 Phase I (Other) 2 countries
Study of two different doses of cabozantinib in progressive, metastatic medullary thyroid cancer Ended

2024-516480-90-00 Phase IV 4 countries CABOZANTINIB
A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with i… Ended

2023-508267-69-00 Phase I (Other) 5 countries

Showing 1–13 of 13 trials

← All sponsors A–Z